Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $PROK
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/30/2024 | Neutral | JP Morgan | |
9/10/2024 | $6.00 | Buy | Guggenheim |
3/7/2024 | $3.00 | Equal-Weight | Morgan Stanley |
1/2/2024 | Buy → Neutral | BofA Securities | |
7/25/2023 | $16.00 | Buy | BTIG Research |
12/21/2022 | $15.00 | Buy | Jefferies |
11/10/2022 | $13.00 | Equal-Weight | Morgan Stanley |
10/18/2022 | $18.00 | Buy | UBS |
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 43rd Annual J.P. Morgan Healthcare ConferenceDate:January 15, 2025Time:7:30am PSTFormat:PresentationWebcast:Link The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December: Evercore HealthCONx ConferenceDate:December 3, 2024Time:8:45am ETFormat:Fireside ChatWebcast:Link Citi Global Healthcare ConferenceDate:December 4, 2024Format:One-on-one meetings The live webcast for the Evercore fireside chat will be accessible through the "Events" section of the Investor Relations tab w
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed in that Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used Presented five posters at the ASN Kidney Week, including one late-breaking clinical trial and four posters on rilparencel's product characterization and MOAEnded the third quarter with $406.8 million in cash and cash equivalents and marketable securities, supporting operations into 2027 WINSTON-SALEM, N.C
JP Morgan initiated coverage on ProKidney Corp.
JP Morgan initiated coverage of ProKidney Corp. with a rating of Neutral
Guggenheim initiated coverage on ProKidney Corp. with a new price target
Guggenheim initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $6.00
Morgan Stanley resumed coverage on ProKidney Corp. with a new price target
Morgan Stanley resumed coverage of ProKidney Corp. with a rating of Equal-Weight and set a new price target of $3.00
Large owner Control Empresarial De Capitales S.A. De C.V. bought $19,999,998 worth of Class A Ordinary Shares (8,264,462 units at $2.42) (SEC Form 4)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
Director Legorreta Pablo G. bought $54,735,340 worth of Class A Ordinary Shares (22,617,909 units at $2.42) (SEC Form 4)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
Control Empresarial De Capitales S.A. De C.V. bought $251,666 worth of Class A Ordinary Shares (177,000 units at $1.42) (SEC Form 4)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
Director Legorreta Pablo G. converted options into 532,535 units of Class A Ordinary Shares and disposed of 532,535 units of Class A Ordinary Shares (SEC Form 4)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
Director Pereira Brian Jg converted options into 757,162 units of Class A Ordinary Shares (SEC Form 4)
4 - PROKIDNEY CORP. (0001850270) (Issuer)
New insider Cowen Aaron claimed ownership of 13,198,766 units of Class A ordinary shares (SEC Form 3)
3 - PROKIDNEY CORP. (0001850270) (Issuer)
ProKidney Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement
8-K - PROKIDNEY CORP. (0001850270) (Filer)
ProKidney Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement
8-K - PROKIDNEY CORP. (0001850270) (Filer)
SEC Form 10-Q filed by ProKidney Corp.
10-Q - PROKIDNEY CORP. (0001850270) (Filer)
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.
Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentiall
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024Strengthened leadership team with appointment of two key hires across Clinical and Technical OperationsEnded the first quarter with $329 million in cash and cash equivalents and marketable securities, su
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. "We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential to preserve kidney function in patients with type 2 diabetes mellitus and advanced kidney disease, we look forward to the REGEN-007 Phase 2 interim data readout mid-year," said Bruce Culleton, Ch
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both PROACT 1 and PROACT 2 Phase 3 trialsManagement to host live webcast today at 8:00 a.m. ET WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical
ProKidney Reports Third Quarter Financial Results
WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023. "Building off of our positive corporate update, and with nearly $400 million in cash, cash equivalents and marketable securities as of September 30th of this year, ProKidney continues to be well capitalized to continue executing on both of our Phase 2 and Phase 3 trials in high-risk CKD patients in need," said James Coulston, Chief Financial Officer at ProKidney. "With cash expected to fund operations into the
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on patients with Stage 3b and 4 diabetic CKD at highest risk of advancing to kidney failure and need for renal replacement therapy Dr. Bruce Culleton appointed ProKidney CEO following Dr. Tim Bertram's transition to advisory role Sufficient capital to fund operations into fourth quarter 2025 ProKidney to host conference call and webcast tomorrow at 8:00 a.m. ET WINSTON-SALEM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellu
Amendment: SEC Form SC 13G/A filed by ProKidney Corp.
SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)
Amendment: SEC Form SC 13G/A filed by ProKidney Corp.
SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)
Amendment: SEC Form SC 13D/A filed by ProKidney Corp.
SC 13D/A - PROKIDNEY CORP. (0001850270) (Subject)